logo

For the Inventor, By the Inventor

Glen Rock, NJ, United States of America

Cortex Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 15

% Expired Patents = 40.0



Trademarks = 1

Forward Citations = 217

Loading Chart...
Loading Chart...

18 inventors (with patents filed for the assignee):

goldMedal Rudolf Mueller (8 out of 11 patents)

silverMedal Leslie Street (7 out of 9 patents)

bronzeMedal Gary A Rogers (5 out of 16 patents)

4.  Steven Lee (3 out of 3 patents)

5.  Christopher M Marrs (2 out of 5 patents)

6.  Gary S Lynch (2 out of 23 patents)

7.  David D Eveleth (2 out of 2 patents)

8.  Judith A Kelleher (2 out of 2 patents)

9.  Carl W Cotman (1 out of 10 patents)

10.  Clayton Harris (1 out of 24 patents)

11.  Matthew Allan (1 out of 1 patent)

12.  Jianjie Huang (1 out of 1 patent)

13.  Stanislaw Rachwal (1 out of 1 patent)

14.  Steven A Johnson (1 out of 1 patent)

15.  David D Eveleth, Jr (1 out of 2 patents)


15 patents:

1. 8642633 - Di-substituted amides for enhancing glutamatergic synaptic responses (2014-02-04),
2. 8507482 - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses (2013-08-13),
3. 8404682 - Di-substituted amides for enhancing glutamatergic synaptic responses (2013-03-26),
4. 8263591 - Bicyclic amides for enhancing glutamatergic synaptic responses (2012-09-11),
5. 8168632 - Bicyclic amide derivatives for the treatment of respiratory disorders (2012-05-01),
6. 8119632 - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses (2012-02-21),
7. 8013003 - Di-substituted amides for enhancing glutamatergic synaptic responses (2011-09-06),
8. 7799913 - Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses (2010-09-21),
9. 6166008 - Treatment of schizophrenia with ampakines and neuroleptics (2000-12-26),
10. 5985871 - Benzoxazine compounds for enhancing synaptic response (1999-11-16),
11. 5736543 - Benzoxazines for enhancing synaptic response (1998-04-07),
12. 5650409 - Benzoyl piperidines/pyrrolidines for enhancing synaptic response (1997-07-22),
13. 5622981 - Use of metabotropic receptor agonists in progressive neurodegenerative (1997-04-22),
14. 5567724 - Alkaline and acid phosphatase inhibitors in treatment of neurological (1996-10-22),
15. 5444042 - Method of treatment of neurodegeneration with calpain inhibitors (1995-08-22),
Company Overview
Cortex Pharmaceuticals, Inc. is a biopharmaceutical company based in Glen Rock, New Jersey, specializing in the development of innovative therapies for neurological disorders. The company focuses on advancing treatments that target cognitive dysfunction and related conditions, leveraging proprietary technologies to enhance drug efficacy. With a commitment to research and development, Cortex aims to address unmet medical needs in the field of neuroscience, contributing to improved patient outcomes and quality of life.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#1 in Glen Rock, NJ

#802 in New Jersey

#21,085 in US

#39,991 in the World

Glen Rock, NJ (US)
Glen Rock, NJ, United States of America

Cortex Pharmaceuticals, Inc.

Forward Citations = 217

18 inventors:

goldMedal Rudolf Mueller (8 out of 11 patents)

silverMedal Leslie Street (7 out of 9 patents)

bronzeMedal Gary A Rogers (5 out of 16 patents)

4.  Steven Lee (3 out of 3 patents)

5.  Christopher M Marrs (2 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cortex Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/cortex-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…